Re: Farmas USA
analisis bueno de AMRN
http://bionapcfa.blogspot.ca/2012/08/musing-on-amarin.html
sube un poco el precio tras el NCE
Those are my assumptions. All that gets me to $21.25. The model is below. I think if they can get NCE, the stock might be worth $23-24 on longer exclusivity. I think if REDUCE-IT hits, which there is precedence to believe it might, then my peak sales estimate of $2.5 billion is low - way low. Vascepa might do north of $4 billion in that case. That would put the stock above $30. But we will not know the outcome of REDUCE-IT for several years. With ANCHOR approved and REDUCE-IT looking good, I think then you might see a take-out. As I noted in my Tweet, I love the idea of AstraZeneca taking Amarin over. It just makes the most sense to me. Others like Lilly, Pfizer, Sanofi, Bristol, and Abbott also make sense.